FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285588687> ?p ?o ?g. }

• W4285588687 endingPage "451" @default.
• W4285588687 startingPage "441" @default.
• W4285588687 abstract "Prostate cancer (PCa) is the most frequently diagnosed cancer in men in Europe. The impact of PCa natural history and therapeutic management on the outcomes of castration-resistant prostate cancer patients with metastasis (mCRPC) remains unclear.The objective of this study was to describe retrospectively patterns of clinical progression through diagnosis sequences before the mCRPC stage and to assess how these sequences impacted patients' disease progression and overall survival at mCRPC stage.Patients with mCRPC were identified from the Prostate Cancer Registry (PCR), an observational study in a real-world setting in 16 countries between 2013 and 2016. Patients were grouped in diagnosis sequences before mCRPC and defined by date of PCa diagnosis, first metastasis, and castration resistance. Distribution of time-to-event variables were estimated using Kaplan-Meier product-limit survival curves for overall survival (OS) and progression-free survival (PFS). Non-adjusted Cox models were conducted for efficacy endpoints (OS, PFS) to estimate hazard ratios between diagnosis sequences.At the end of study, 2859 mCRPC patients were included in this analysis. Among mCRPC four diagnosis sequences were identified: 35% developed metastases (mHSPC) before becoming castration resistant (sequence 1, metachronous mHSPC), 10% developed castration resistance (nmCRPC) before metastases (sequence 2), 27% developed metastases and castration resistance within 4 months (sequence 3) and 28% of patients were de novo mHSPC (sequence 4). Median OS was 17.7 months (interquartile range (IQR): 8.8-29.9) and PFS was 6.4 months (IQR: 3.2-12.0). The univariate analyses showed no correlation between mCRPC patients' OS or PFS and the diagnosis sequence.This large European study describe four different patterns of prostate cancer progression to mCRPC stage. Our results indicate that patient survival becomes comparable after progression to mCRPC, regardless of the diagnosis sequence.ClinicalTrials.gov identifier NCT02236637; registered September 2014." @default.
• W4285588687 created "2022-07-16" @default.
• W4285588687 creator A5004430458 @default.
• W4285588687 creator A5021286886 @default.
• W4285588687 creator A5026059401 @default.
• W4285588687 creator A5046987669 @default.
• W4285588687 creator A5058699283 @default.
• W4285588687 creator A5064791245 @default.
• W4285588687 creator A5066054798 @default.
• W4285588687 creator A5071314071 @default.
• W4285588687 creator A5086087911 @default.
• W4285588687 date "2022-07-01" @default.
• W4285588687 modified "2023-10-05" @default.
• W4285588687 title "Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry" @default.
• W4285588687 cites W1506304343 @default.
• W4285588687 cites W1988708470 @default.
• W4285588687 cites W2004722883 @default.
• W4285588687 cites W2053948486 @default.
• W4285588687 cites W2055346449 @default.
• W4285588687 cites W2118370975 @default.
• W4285588687 cites W2138320929 @default.
• W4285588687 cites W2142466432 @default.
• W4285588687 cites W2148987788 @default.
• W4285588687 cites W2149459776 @default.
• W4285588687 cites W2150865892 @default.
• W4285588687 cites W2166918329 @default.
• W4285588687 cites W2168242827 @default.
• W4285588687 cites W2754866939 @default.
• W4285588687 cites W2787804990 @default.
• W4285588687 cites W2889646458 @default.
• W4285588687 cites W2898661793 @default.
• W4285588687 cites W2938589827 @default.
• W4285588687 cites W2947014957 @default.
• W4285588687 cites W2947893479 @default.
• W4285588687 cites W3000208382 @default.
• W4285588687 cites W3024065396 @default.
• W4285588687 cites W3031020438 @default.
• W4285588687 cites W3033684926 @default.
• W4285588687 cites W3035356494 @default.
• W4285588687 cites W3092776892 @default.
• W4285588687 cites W3151123859 @default.
• W4285588687 cites W3191534679 @default.
• W4285588687 doi "https://doi.org/10.1007/s11523-022-00899-6" @default.
• W4285588687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35841526" @default.
• W4285588687 hasPublicationYear "2022" @default.
• W4285588687 type Work @default.
• W4285588687 citedByCount "2" @default.
• W4285588687 countsByYear W42855886872023 @default.
• W4285588687 crossrefType "journal-article" @default.
• W4285588687 hasAuthorship W4285588687A5004430458 @default.
• W4285588687 hasAuthorship W4285588687A5021286886 @default.
• W4285588687 hasAuthorship W4285588687A5026059401 @default.
• W4285588687 hasAuthorship W4285588687A5046987669 @default.
• W4285588687 hasAuthorship W4285588687A5058699283 @default.
• W4285588687 hasAuthorship W4285588687A5064791245 @default.
• W4285588687 hasAuthorship W4285588687A5066054798 @default.
• W4285588687 hasAuthorship W4285588687A5071314071 @default.
• W4285588687 hasAuthorship W4285588687A5086087911 @default.
• W4285588687 hasBestOaLocation W42855886871 @default.
• W4285588687 hasConcept C119060515 @default.
• W4285588687 hasConcept C121608353 @default.
• W4285588687 hasConcept C126322002 @default.
• W4285588687 hasConcept C143998085 @default.
• W4285588687 hasConcept C144301174 @default.
• W4285588687 hasConcept C146357865 @default.
• W4285588687 hasConcept C151730666 @default.
• W4285588687 hasConcept C207103383 @default.
• W4285588687 hasConcept C2776551883 @default.
• W4285588687 hasConcept C2778527826 @default.
• W4285588687 hasConcept C2779013556 @default.
• W4285588687 hasConcept C2780192828 @default.
• W4285588687 hasConcept C38180746 @default.
• W4285588687 hasConcept C44249647 @default.
• W4285588687 hasConcept C50382708 @default.
• W4285588687 hasConcept C61367390 @default.
• W4285588687 hasConcept C71924100 @default.
• W4285588687 hasConcept C86803240 @default.
• W4285588687 hasConceptScore W4285588687C119060515 @default.
• W4285588687 hasConceptScore W4285588687C121608353 @default.
• W4285588687 hasConceptScore W4285588687C126322002 @default.
• W4285588687 hasConceptScore W4285588687C143998085 @default.
• W4285588687 hasConceptScore W4285588687C144301174 @default.
• W4285588687 hasConceptScore W4285588687C146357865 @default.
• W4285588687 hasConceptScore W4285588687C151730666 @default.
• W4285588687 hasConceptScore W4285588687C207103383 @default.
• W4285588687 hasConceptScore W4285588687C2776551883 @default.
• W4285588687 hasConceptScore W4285588687C2778527826 @default.
• W4285588687 hasConceptScore W4285588687C2779013556 @default.
• W4285588687 hasConceptScore W4285588687C2780192828 @default.
• W4285588687 hasConceptScore W4285588687C38180746 @default.
• W4285588687 hasConceptScore W4285588687C44249647 @default.
• W4285588687 hasConceptScore W4285588687C50382708 @default.
• W4285588687 hasConceptScore W4285588687C61367390 @default.
• W4285588687 hasConceptScore W4285588687C71924100 @default.
• W4285588687 hasConceptScore W4285588687C86803240 @default.
• W4285588687 hasFunder F4320337415 @default.
• W4285588687 hasIssue "4" @default.
• W4285588687 hasLocation W42855886871 @default.

• next